Recent News Stories Highlight Stellar Biotechnologies
November 22, 2011 09:05 ET
|
Stellar Biotechnologies, Inc.
PORT HUENEME, CA--(Marketwire - Nov 22, 2011) - Stellar Biotechnologies, Inc. "Stellar" (TSX-V: KLH) (PINKSHEETS: SBOTF) is pleased to report two recent news stories on the company, by the National...
Number of Monoclonal Antibody Products in Development Continues to Increase, According to Tufts Center for the Study of Drug Development
November 08, 2011 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Nov 8, 2011) - Developers are steadily increasing the number of monoclonal antibody products -- known as mAbs -- for which they are initiating clinical studies, extending...
Drug Companies Are Using Innovative Partnerships to Spur Development, According to Tufts Center for the Study of Drug Development
October 06, 2011 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Oct 6, 2011) - Responding to strong and growing pressure to reduce development times and increase the output of new medicines, drug companies are engaging in innovative...
Majority of Clinical Trial Protocols Are Amended, but One-Third of Those Changes Are Avoidable, According to Tufts Center for the Study of Drug Development
September 13, 2011 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Sep 13, 2011) - Nearly 60 percent of all protocols used in clinical trials for new drugs are amended during the trial. Moreover, one-third of those changes could have been...
Landmark Clinical Research With the On-X Heart Valve in a Poorly Anticoagulated South African Patient Group to be Presented at Major U.S. Heart Centers
September 01, 2011 07:58 ET
|
On-X Life Technologies Inc.
AUSTIN, Texas, Sept. 1, 2011 (GLOBE NEWSWIRE) -- On-X® Life Technologies, Inc. (On-X LTI) announced today that Mervyn Williams, M.D., of Port Elizabeth, South Africa, will present the results of...
Growing Regulatory Requirements Worldwide Challenge Drug Developers, According to Tufts Center for the Study of Drug Development
August 09, 2011 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Aug 9, 2011) - As pharmaceutical and biopharmaceutical companies increase the number of clinical trials they conduct in emerging global markets, growing regulatory...
Stellar Biotechnologies Announces a Strategic Agreement for Marketing and Sales With SAFC(R)
August 03, 2011 16:05 ET
|
Stellar Biotechnologies, Inc.
PORT HUENEME, CA--(Marketwire - Aug 3, 2011) - Stellar Biotechnologies, Inc. "Stellar" (TSX-V: KLH) (PINKSHEETS: SBOTF) is pleased to announce they have entered into an agreement for marketing and...
Lack of Clinically Useful Diagnostics Hinders Growth in Personalized Medicines, According to Tufts Center for the Study of Drug Development
July 19, 2011 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Jul 19, 2011) - Lack of evidence that links diagnostic tests to health outcomes has led payers in the United States to be skeptical about the clinical usefulness of those...
Biotech Drug Approvals in the U.S. Nearly Doubled in the Last Decade, According to Tufts Center for the Study of Drug Development
May 10, 2011 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - May 10, 2011) - U.S. regulatory approvals for new biopharmaceuticals nearly doubled in the last decade, compared to the 1990s, according to the Tufts Center for the Study of...
Drug Developers Actively Improving Efficiency of Clinical Trials, According to Tufts Center for the Study of Drug Development
April 26, 2011 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Apr 26, 2011) - Looking to improve the operational efficiency of clinical trials, drug developers are actively pursuing new strategies that include collaborating with...